Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
NCT01236547
Completed
This randomized phase II trial studies the side effects and how well intensity-modulated radiation therapy (IMRT) and paclitaxel with or without pazopanib hydrochloride works in treating patients with anaplastic thyroid cancer. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/28/2022
Locations: Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California +11 locations
Conditions: Thyroid Gland Anaplastic Carcinoma
Register for Updates
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
NCT01966471
Completed
This two-arm, randomized, open-label, multicenter study will evaluate the efficacy and safety of trastuzumab emtansine in combination with pertuzumab versus trastuzumab in combination with pertuzumab and a taxane as adjuvant therapy in participants with human epidermal growth (HER) factor 2 (HER2)-positive primary invasive breast cancer. Following surgery and anthracycline-based chemotherapy, participants will receive either trastuzumab emtansine at a dose of 3.6 milligrams per kilogram (mg/kg)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2022
Locations: Kaiser Permanente - Oakland, Oakland, California +10 locations
Conditions: Breast Cancer
Register for Updates
A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors
NCT03330106
Completed
The purpose of this study is to characterize the effects of 25 and 50 milligram per square meter (mg/m\^2) pevonedistat on the Fridericia corrected QT interval (QTcF) of the electrocardiogram (ECG).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2022
Locations: Sarcoma Oncology Center, Santa Monica, California
Conditions: Advanced Solid Neoplasm
Register for Updates
A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer
NCT03086369
Completed
The purpose of this study is to determine the safety and efficacy of nab-paclitaxel and gemcitabine with or without olaratumab in the treatment of first-line metastatic pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2022
Locations: Comprehensive Blood and Cancer Center, Bakersfield, California +5 locations
Conditions: Metastatic Pancreatic Cancer
Register for Updates
Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer
NCT00573131
Terminated
OncoGel is a new experimental drug delivery system that allows the slow continuous release of paclitaxel (an approved intravenous anticancer drug), from a gel (ReGel) over a long period of time. The gel will disappear in 4 to 6 weeks as it releases the paclitaxel. The protocol is directed towards evaluating the efficacy and safety of paclitaxel delivered as a local, intralesional treatment when used in combination with chemotherapy (cisplatin and 5-FU) and radiation therapy before surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2022
Locations: University of California San Diego, San Diego, California
Conditions: Esophageal Cancer, Adenocarcinoma of the Esophagus, Squamous Cell Carcinoma
Register for Updates
Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients
NCT01461915
Terminated
This randomized, Phase 2, open label study aims to assess the efficacy and safety of gemcitabine + nab paclitaxel with or without dociparstat (ODSH) as first line treatment of metastatic pancreatic cancer. This study consists of 2 periods: a Run-in Period and a Randomized Period.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/02/2022
Locations: Disney Family Cancer Center, Burbank, California +2 locations
Conditions: Metastatic Pancreatic Cancer
Register for Updates
Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
NCT03412799
Completed
This is an open-label phase 1A/1B study to assess the safety, tolerability and pharmacokinetics of SBP-101 when combined with nab-paclitaxel and gemcitabine in subjects with previously untreated metastatic pancreatic ductal adenocarcinoma and to identify a recommended phase 2 dose. The study will also assess preliminary efficacy of the 3-drug treatment combination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2022
Locations: Scripps MD Anderson Cancer Center, La Jolla, California
Conditions: Pancreatic Cancer Metastatic, Pancreatic Cancer Stage IV, Stage IV Pancreatic Cancer
Register for Updates
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer
NCT00655876
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Cetuximab may s... Read More
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
05/23/2022
Locations: Auburn Radiation Oncology, Auburn, California +12 locations
Conditions: Esophageal Cancer
Register for Updates
High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT00533949
Completed
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel, carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet know... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2022
Locations: Mercy Cancer Center at Mercy San Juan Medical Center, Carmichael, California +13 locations
Conditions: Lung Cancer, Radiation Toxicity
Register for Updates
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
NCT00979212
Completed
RATIONALE: Drugs used in chemotherapy (CT), such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy (RT) uses high-energy x-rays to kill tumor cells. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. G... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2022
Locations: Mercy Cancer Center at Mercy San Juan Medical Center, Carmichael, California +1 locations
Conditions: Lung Cancer
Register for Updates
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
NCT01547741
Unknown
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of breast cancer cells, either by killing the cells or by stopping them from dividing. Giving the drugs in different combinations may kill more breast cancer cells. Giving combination chemotherapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens and their side effects and comparing how well they work in... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/13/2022
Locations: Kaiser Anaheim Medical Center, Anaheim, California +66 locations
Conditions: Breast Cancer
Register for Updates
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
NCT02711137
Terminated
The purpose of the Study is to select a dose and assess the safety and tolerability of INCB057643 as a monotherapy (Part 1 and Part 2) and in combination with standard-of-care (SOC) agents (Part 3 and Part 4) for subjects with advanced malignancies. Part 1 will determine the maximum tolerated dose of INCB057643 and/or a tolerated dose that demonstrates sufficient pharmacologic activity. Part 2 will further evaluate the safety, preliminary efficacy, PK, and PD of the dose(s) selected in Part 1 i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2022
Locations: University of California, La Jolla, California
Conditions: Solid Tumors
Register for Updates